Loading organizations...
Founded in 2016 by Chief Executive Officer Hans Keirstead, AIVITA Biomedical is a biotechnology company based in Irvine, California. The organization develops personalized stem cell based therapies and vaccines for late stage solid tumors like melanoma and ovarian cancer. Utilizing a hybrid business model, the enterprise generates revenue from its commercial consumer skincare brand, ROOT of SKIN, to directly fund ongoing clinical oncology research. Operating with an estimated 10 to 50 employees, the firm has raised over $32 million in total venture funding and secured approximately $22 million in additional research grants. The company's clinical pipeline recently produced positive survival data from a Phase 2 clinical trial of AV-GBM-1, a personalized immunotherapy for glioblastoma, and is guided by Chief Science Officer Gabriel Nistor, Chief Medical Officer Robert Dillman, and board members Philippe Schaison and Matthew Katz.
AIVITA Biomedical has raised $43.7M across 4 funding rounds.
AIVITA Biomedical has raised $43.7M in total across 4 funding rounds.
AIVITA Biomedical has raised $43.7M across 4 funding rounds. Most recently, it raised $25.0M Series B in February 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 25, 2020 | $25M Series B | Matthew Katz | — | Announced |
| Jul 18, 2018 | $1.7M Venture Round | California Institute For Regenerative Medicine | — | Announced |
| Jun 12, 2018 | $15M Series B | SFC Capital | — | Announced |
| Jun 11, 2016 | $2M Series A | Alexander SUH | — | Announced |
AIVITA Biomedical has raised $43.7M in total across 4 funding rounds.
AIVITA Biomedical's investors include Matthew Katz, California Institute for Regenerative Medicine, SFC Capital, Alexander Suh.
